1. Introduction {#s0005}
===============

Malaria and iron deficiency (ID) are major public health problems for children living in sub-Saharan Africa. Malaria caused an estimated 437,000 deaths in young African children in 2013 ([@bb0210]) and \> 70% of children have asymptomatic malaria in some malaria-endemic areas ([@bb0185]), while ID is thought to impair cognitive development ([@bb0140]) and is the leading cause of years lived with disability in sub-Saharan Africa ([@bb0200]). Hepcidin, the iron-regulatory hormone, may provide a critical link between malaria and ID. Hepcidin controls the absorption and distribution of iron ([@bb0180]) and is thought to play a role in the innate immune response by restricting iron availability for pathogen growth ([@bb0170], [@bb0165]). The synthesis of hepcidin is regulated by diverse, often competing, physiological processes, including iron stores, inflammation and erythropoietic drive ([@bb0175], [@bb0130]). Malaria also alters hepcidin concentrations. Febrile malaria is associated with increased plasma concentrations ([@bb0190], [@bb0155], [@bb0150], [@bb0135]), while severe and complicated malaria is associated with reduced plasma levels in African children ([@bb0150], [@bb0145]). Asymptomatic malaria also increased plasma levels in Indonesian school-age children ([@bb0160]). In turn, we hypothesized that hepcidin may mediate the risk of malaria and other infections by restricting iron availability ([@bb0170], [@bb0165]). Intriguing data from mouse models suggest that hepcidin may play a critical role in host defence against malaria ([@bb0205]), malaria superinfection ([@bb0195]), and bacterial infection ([@bb0005]), but how this may work in children is not known. In the current study, our objectives were to assess the effect of a range of factors including age, gender and malaria on hepcidin concentrations and in turn to assess the effect of hepcidin concentrations on subsequent infectious risk in a longitudinal surveillance study of Kenyan children intensively monitored for malaria and other febrile illnesses.

2. Materials and Methods {#s0010}
========================

2.1. Ethics Statement {#s0025}
---------------------

Individual written informed consent was obtained from the parents of all study participants and ethical permission for the study was granted by the Kenya Medical Research Institute (KEMRI)/National Ethical Review Committee.

2.2. Participants and Procedures {#s0030}
--------------------------------

The current study was nested within an ongoing, longitudinal cohort study evaluating the history and acquisition of natural immunity to malaria in children living in Kilifi District on the Kenyan coast ([@bb0010]). The current study involving 324 children was conducted during an 18-month period between November 2001 and May 2003 and included all children \< 8 years of age within the Ngerenya study area ([Fig. 1](#f0005){ref-type="fig"}). Participants were monitored for malaria and other diseases by weekly active surveillance as previously described ([@bb0010]). Two cross-sectional surveys were conducted at 6 and 12 months after the start of the study during which venous blood samples were collected. Children exited the study if informed consent was withdrawn or if they moved out of the study area for a period of \> 2 months.

2.3. Laboratory Procedures {#s0035}
--------------------------

*Plasmodium falciparum* parasitaemia was determined as previously described ([@bb0015]). Haemoglobin typing (HbA and HbS) was by electrophoresis (Helena Laboratories, Beaumont, TX) while α-thalassemia genotyping was by PCR ([@bb0020]). Plasma concentrations of ferritin, soluble transferrin receptor (sTfR) and C-reactive protein (CRP) were determined as previously described ([@bb0130], [@bb0015]). IgG antibodies against whole *P*. *falciparum* schizont extract and against the 3D7 allele of apical membrane antigen 1 (AMA1) and merozoite surface protein 2 (MSP2) were assayed by enzyme linked immunosorbent assay (ELISA) ([@bb0025]).

Plasma hepcidin was quantified by competitive ELISA (Hepcidin-25 (human) EIA Kit, Bachem) ([@bb0130]). Standards and samples were analyzed in duplicate or triplicate. Samples giving readings outside the standard linear region were repeated at appropriate dilutions. Readings with coefficient of variation \> 10% were repeated. The lower limit of detection (LOD) of hepcidin was estimated at 0.08 ng/ml based on the hepcidin value corresponding to 3 standard deviations below the mean no hepcidin blank optical density at 450 nm; undiluted samples giving reading of \< LOD were reported as LOD/2 = 0.04 ng/ml.

2.4. Case Definitions {#s0040}
---------------------

Clinical malaria was defined as a fever (axillary temperature ≥ 37.5 °C) in conjunction with a positive blood smear for *P. falciparum* parasites at any density for children age \< 1 year or at a density of \> 2500 parasites/μl for children age ≥ 1 year ([@bb0010]). Asymptomatic malaria was defined during cross-sectional surveys as smear positive *P. falciparum* malaria in the absence of fever or other symptoms of clinical illness, while non-malarial fever was defined as a fever in conjunction with a negative malaria blood smear. Inflammation was defined as plasma CRP concentration of ≥ 5 mg/l ([@bb0030]). ID was defined as a ferritin concentration of \< 12 μg/l, or \< 30 μg/l in the presence of inflammation respectively ([@bb0130], [@bb0035]). The ferritin index, a measure of bone marrow iron depletion, was defined as soluble transferrin receptor/log ferritin ([@bb0040]).

2.5. Statistical Analyses {#s0045}
-------------------------

All analyses were conducted using STATA v.12.0 (StataCorp. College Station, TX). Associations between hepcidin concentration (or other variables such as iron status) and independent parameters were evaluated using generalized estimating equation (GEE)-based linear regression models that included an exchangeable correlation structure and a robust variance estimator to account for correlation between measurements at two time points from the same child. Analyses were age-adjusted as appropriate. We did not restrict fitting independent parameters, such as age, to linear effects. We allowed for nonlinear effects by fitting and significance testing multivariable fractional polynomials with use of the Royston and Altman algorithm entering hepcidin concentration and other variables simultaneously in the model. This allowed the model to optimize the model fit using power and log functions to approximate the shape of the relationship of the parameter with hepcidin ([@bb0045]). The association between hepcidin concentration and the subsequent risk of clinical malaria or non-malarial fever was evaluated using Cox proportional hazards analysis during the 6-month period of monitoring after each cross-sectional survey. Therefore, each of the 324 children could contribute up to 2 periods of observation and the sandwich estimator was used to cluster analysis by individual ([@bb0050]).

Multivariable models included covariates with a significance of p ≤ 0·1 in univariable models. We used p \< 0·05 to interpret the findings in the final multivariable model. For clinical malaria hazards ratios were adjusted for age, ethnicity, sickle cell trait and period of monitoring and for non-malarial fever hazards ratios were adjusted for age in years and period of monitoring.

2.6. Role of the Funding Source {#s0050}
-------------------------------

This work was funded by the Oxford University Clinical Academic Graduate School; The Academy of Medical Sciences with The Wellcome Trust, The British Heart Foundation, Arthritis Research UK (to SHA); a Beit Memorial Fellowship for Medical Research; an MRC New Investigator award; the National Institute for Health Research Oxford Biomedical Research Centre (to HD); a Senior Wellcome Trust Fellowship (grant number 091758 to TNW); a Senior Research Fellowship to JGB; and the European Union Framework Programme Seven European Virtual Institute of Malaria Research Consortium (grant number 242095 to TNW). The sponsors had no role in study design, data collection, data analyses, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and the final responsibility for the decision to submit for publication.

3. Results {#s0015}
==========

A total of 324 children were included in the study with an average followup time of 7·4 months. [Table 1](#t0005){ref-type="table"} describes the characteristics of the study population. Median age was 47·0 months at the mid-point of longitudinal follow-up (range; 4·9 to 97·1 months) and 54·6% were male. The overall geometric mean plasma hepcidin concentration was 2·45 ng/ml (95% CI; 2·08, 2·90; range; 0·04 to 176·56 ng/ml). ID and inflammation were common at 46% (262/572) and 18% (102/572) respectively. Asymptomatic malaria parasitaemia was also common: 12% (70/582) of routine blood smears were positive for *P*. *falciparum* with a mean parasite density of 909 parasites/μl (range; 40 to 380,000 parasites/μl). We found no significant association between geometric mean hepcidin concentrations and either sickle cell trait (for HbAA 2·48 ng/ml; 95% CI 2·08, 2·97; and for HbAS 2·15 ng/ml; 1·32, 3·50; p = 0·63) or α-thalassaemia (for αα/αα 2·64 ng/ml; 95% CI 1·96, 3·56; for − α/αα 2·31 ng/ml; 1·82, 2·93; p = 0·56 and for − α/− α 2·27 ng/ml; 1·48, 3·50; p = 0·61).

3.1. Hepcidin Concentration Varies by Age and in Infancy by Sex {#s0055}
---------------------------------------------------------------

Plasma hepcidin concentration varied markedly by age (ß = − 0·1; − 0·06, − 0·13; p \< 0·0005 in a GEE-based model), while the best-fit fractional polynomial for the age profile of hepcidin suggested that levels were the highest in the youngest children, decreased very rapidly in infancy and then declined slowly in childhood ([Fig. 2](#f0010){ref-type="fig"}A). These findings may be explained by age-related differences in the strength of stimuli determining hepcidin expression. The best-fit for the age profile of ferritin suggested that levels fell very rapidly in infancy reaching a nadir between 1 and 2 years of age and then gradually increased. Soluble TfR levels and the ferritin index increased sharply in infancy, while the age profile of CRP suggested a simple linear decrease in inflammation with increasing age ([Fig. 3](#f0015){ref-type="fig"}A--D). The prevalence of asymptomatic malaria parasitaemia increased with increasing age ([Table 2](#t0010){ref-type="table"}). We found no overall difference in hepcidin concentrations by sex in all age groups combined (2·75 ng/ml; 2·11, 3·57 for females vs. 2·24; 1·80, 2·78 for males; p = 0·40 in an age-adjusted model), however female infants had markedly higher concentrations (12·32 ng/ml; 95% CI 7·54, 20·12) compared to male infants (5·79 ng/ml; 3·44, 9·76; p = 0 · 009).

3.2. Hepcidin Concentration is Influenced by Iron Stores, Erythropoiesis and Inflammation {#s0060}
-----------------------------------------------------------------------------------------

Ferritin, sTfR, and CRP levels explained 37.5%, 37.3%, and 10.2% of the variance in hepcidin concentrations respectively (p \< 0.0005 for each). Hepcidin concentrations were very low in children with ID (0·71 ng/ml; 95% CI 0·55, 0·92) in comparison to those without (6·64 ng/ml; 95% CI 5·71, 7·70; p \< 0·0005). The best-fit fractional polynomials suggested that hepcidin concentrations increased with increasing ferritin and CRP and decreased with increasing sTfR and ferritin index ([Fig. 2](#f0010){ref-type="fig"}B--E). Inflammation (CRP ≥ 5 mg/l) was associated with increased hepcidin concentrations (7·57 ng/ml; 95% CI 5·56, 10·31 compared to 1·91; 1·58, 2·30; p \< 0·0005, in those without inflammation).

3.3. Hepcidin Concentration is Positively Associated with Asymptomatic Malaria {#s0065}
------------------------------------------------------------------------------

Hepcidin concentrations were more than doubled in individuals with asymptomatic *P*. *falciparum* parasitaemia (5·29 ng/ml; 3·39, 8·25 compared to 2·18 ng/ml; 1·82, 2·61; p \< 0·0005 in aparasitaemic individuals) and malaria parasitaemia explained 7% of the variation in hepcidin (p \< 0·0005). Parasite density, ID, inflammation, and age modified the effects of parasitaemia on hepcidin ([Figs. 2](#f0010){ref-type="fig"}F, [4](#f0020){ref-type="fig"}). Among parasitized children those with ID had markedly lower hepcidin concentrations compared to those without (1·41 ng/ml; 0·49, 4·0 vs. 8·14 ng/ml; 5·26, 12·6; p \< 0·0005). Moreover, parasitaemia increased hepcidin concentrations both in the absence and presence of inflammation ([Fig. 4](#f0020){ref-type="fig"}A). Hepcidin concentrations were higher among younger parasitaemic children than older (13·47 ng/ml; for 3--5 years old compared to 3·14 ng/ml for 5--8 years old; β -0·64; − 0·27, − 1·0; p = 0 · 001, [Figs. 2](#f0010){ref-type="fig"}A and [4](#f0020){ref-type="fig"}B). Similarly, ferritin levels were higher in younger parasitaemic children ([Fig. 3](#f0015){ref-type="fig"}A), although CRP and parasite density did not differ significantly between age groups ([Table 2](#t0010){ref-type="table"}).

3.4. Hepcidin Concentration is Positively Associated with Antibodies to *P. falciparum* Antigens {#s0070}
------------------------------------------------------------------------------------------------

We then assessed whether hepcidin concentrations correlated with antibodies to *P*. *falciparum* antigens. In age-adjusted GEE-based models hepcidin concentrations were positively associated with antibody titres to schizont extract, AMA1, and MSP2 (β 0·41; 0·29, 0·53; p \< 0·0005; β 0·13; 0·02, 0·23; p = 0·02, and β 0·23; 0·13, 0·33; p \< 0·0005 respectively). We found a significant interaction between age and antibody titres to AMA1 in predicting hepcidin concentrations (p = 0·01) and a trend towards an interaction with MSP2 (p = 0·08), so that in younger children a smaller unit change in AMA1 or MSP2 was associated with a much larger unit change in hepcidin compared with older children. We found no interaction between age and antibody titres to schizont extract in predicting hepcidin concentrations.

3.5. Recent Malaria, but not Non-malarial Fever, Alters Hepcidin Concentrations {#s0075}
-------------------------------------------------------------------------------

We next evaluated whether hepcidin concentrations varied with time after a clinical malaria or non-malarial fever episode. The best-fit fractional polynomial of the time profile of hepcidin after treatment for clinical malaria suggested that hepcidin concentrations declined steeply in the first week, then more slowly over the subsequent weeks ([Fig. 5](#f0025){ref-type="fig"}A). However, we found no significant difference in hepcidin concentration attributable to non-malarial febrile illnesses ([Fig. 5](#f0025){ref-type="fig"}B).

3.6. Hepcidin Concentration does not Predict the Subsequent Risk of Malaria or Non-malarial Fever {#s0080}
-------------------------------------------------------------------------------------------------

Finally, we tested the hypothesis that hepcidin concentrations influence the subsequent risk of malaria and non-malarial fever. Overall, we observed 148 first or only episodes of clinical malaria and 130 first or only episodes of non-malarial fever during 2402 months of monitoring. Survival plots for clinical malaria and non-malarial fever by hepcidin tertile are shown in [Fig. 6](#f0030){ref-type="fig"}. In univariable Cox analyses we observed a trend towards a reduced risk of clinical malaria with higher hepcidin concentrations (HR 0.85; 0.71, 1.01; p = 0·07), an effect that was lost on adjustment for other variables (adjusted HR 1.08; 0.90, 1.30; p = 0.41, [Table 3](#t0015){ref-type="table"}). We similarly found no association between hepcidin and the subsequent risk of non-malarial febrile illness ([Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0020}
=============

Both malaria and ID are important public health problems in African children. In the current study 12% of children were parasitaemic and 46% had ID. Hepcidin concentrations fell rapidly in infancy and then more slowly with increasing age, while female infants had higher concentrations than males. We found that asymptomatic malaria was associated with significantly elevated hepcidin concentrations, which were proportional to parasite density and modified by age, inflammation, and the presence of ID. Furthermore, hepcidin was positively associated with antibody titres to *P*. *falciparum* antigens. Concentrations fell rapidly and then slowly after treatment of clinical malaria, but were not altered by non-malarial febrile illnesses. Nevertheless, hepcidin concentrations did not predict the subsequent risk of malaria or other febrile illnesses.

We found a non-linear association between age and hepcidin. In agreement with a study in 3--12-month old Zimbabwean infants ([@bb0055]), hepcidin concentrations were the highest in the youngest children and decreased dramatically in infancy ([Fig. 2](#f0010){ref-type="fig"}A). We add to this that hepcidin concentrations are the highest in the first 3 months of life. However, in contrast to European studies, which showed either no change or an increase in hepcidin with age ([@bb0060], [@bb0065]), we found a slow decline in hepcidin with increasing age. These findings might be explained by age-specific differences in the strength of hepcidin stimuli (such as iron stores, erythropoietic drive, and inflammation) ([Fig. 3](#f0015){ref-type="fig"}), and we hypothesize that different environmental conditions may influence hepcidin signalling at varying ages in European children. In agreement with a study in Kenyan infants ([@bb0070]), we found that hepcidin concentrations were about twice as high in female infants compared to males.

Ferritin, sTfR and CRP explained 37·5%, 37·3%, and 10·2% of the variance in hepcidin respectively (p \< 0·0005 for each). In agreement with a study in Indonesian school children ([@bb0160]), asymptomatic malaria was also associated with an increase in plasma hepcidin (explaining 7% of variance; p \< 0·0005), both in the presence and absence of inflammation, suggesting that malaria regulates hepcidin via non-inflammatory, as well as inflammatory pathways ([@bb0075]). We add that hepcidin levels are proportional to parasite density in asymptomatic infection, as observed in febrile malaria ([@bb0190], [@bb0150]), but not in severe infection ([@bb0145]). Hepcidin concentrations were markedly higher in younger compared to older parasitized children, suggesting that iron absorption is more likely to be impaired in younger children. Finally, among children with parasitaemia, hepcidin levels were markedly lower in those with ID than those without ID, suggesting that malaria-mediated up-regulating stimuli may be overruled by iron demand and erythropoietic stimuli down-regulating hepcidin synthesis. Thus, children with ID and parasitaemia might be in danger of receiving iron if hepcidin-guided supplementation was implemented without malaria screening.

Antibodies to malaria antigens are sensitive biomarkers of population-level malaria exposure and may be useful surveillance tools for malaria control and elimination ([@bb0080]). We investigated whether malaria antibodies might reflect malaria-induced hepcidin levels. We found that plasma hepcidin concentrations were strongly positively associated with antibodies to *P*. *falciparum* antigens in age-adjusted models. For AMA1 and MSP2 we found interactions between age and antibody titres so that in younger children a small increase in antibody titres was associated with a large increase in hepcidin concentrations, while in older children increased antibody titres had little effect on hepcidin. This agrees with our study showing that these antibodies act as measures of exposure in younger children with lower immunity and as measures of protective immunity in older children with higher antibody titres ([@bb0085]). By contrast antibodies to schizont extract were strongly positively associated with hepcidin concentrations regardless of age, which might be explained by their shorter half-life and high rates of sero-reversion at all ages ([@bb0090]). Taken together, these data suggest that sero-surveillance tools may be of use to identify population-level malaria-induced hepcidin, particularly in younger children, with relevance to programmes to restore healthy iron status.

We next evaluated the profile of hepcidin concentrations over a 3-month period after exposure to and treatment of febrile clinical malaria. In agreement with other studies in African children we found that concentrations were initially very high ([@bb0190], [@bb0155], [@bb0150], [@bb0145]); but fell very rapidly in the first week following treatment of febrile malaria and more slowly in the subsequent weeks ([Fig. 5](#f0025){ref-type="fig"}A) ([@bb0155], [@bb0150]). Contrary to expectations, non-malarial febrile illnesses were not significantly associated with hepcidin concentrations ([Fig. 5](#f0025){ref-type="fig"}B), although the fact that diagnoses were not assigned to non-malarial febrile illnesses is a limitation of the study. However, in agreement with this finding, children with both inflammation and malaria had markedly higher hepcidin concentrations than those with inflammation alone (p \< 0.0005, [Fig. 4](#f0020){ref-type="fig"}A), suggesting that malaria may have a more pronounced effect on hepcidin synthesis than other febrile illnesses.

Finally we hypothesized that hepcidin concentrations might influence the subsequent risk of malaria. Intriguing data from mouse studies suggest that hepcidin might play a role in modulating clinical malaria ([@bb0205], [@bb0195]), but we are not aware of any previous studies that have investigated this possibility in humans. After adjustment for potential confounders, we found no significant association between hepcidin and the subsequent risk of either *P*. *falciparum* malaria or non-malarial fever. A number of possible explanations can be put forward for this negative finding. It is possible that, in contrast to mouse studies ([@bb0205]), hepcidin concentrations are not associated with severity of malaria or other infections in humans, perhaps due to hepcidin-independent iron restriction ([@bb0095]). However, if they are, we may have failed to detect an effect for a number of reasons. Firstly, baseline hepcidin may not influence hepcidin at the time of, or just prior to, acute malaria infection and a limitation of our study is that hepcidin was not measured routinely at the time of acute malaria. Second, given that hepcidin is controlled by multiple competing stimuli ([@bb0100]), hepcidin might only influence the subsequent risk of infection when very strong down-regulatory signals from ID and erythropoietic drive overwhelm weaker up-regulatory signals from malaria and other infections ([@bb0150], [@bb0105]). However, the study cohort consisted of 'healthy' community-based children. Finally, there may also be counter-balancing effects, for example a reduced risk of malaria due to ID ([@bb0015], [@bb0110]) may counter a protective effect of higher hepcidin concentrations: all questions for future studies.

In conclusion, we have shown that asymptomatic and recent febrile malaria both significantly increase hepcidin in a population of children where ID is an important cause of morbidity. Given that dietary iron absorption is impaired by elevated hepcidin ([@bb0115], [@bb0120], [@bb0125]), our data suggest that asymptomatic and febrile malaria contribute to the high prevalence of ID in African children. Unless malaria episodes are controlled, iron supplementation may be ineffective because of hepcidin-mediated poor iron absorption. Strategies to prevent and eliminate malaria may therefore have the added benefit of addressing an important cause of ID for children living in sub-Saharan Africa.
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![Study construction. A total of 324 children were recruited to the study; 245 contributed data to both the May and October surveys, 48 to the May survey only and 31 to the October survey only.](gr1){#f0005}

![Multiple fractional polynomials of determinants of hepcidin concentrationby malaria parasitaemia. Scatter plot of log hepcidin concentration (y axis) against: A) age in years (x axis) with the fitted fractional polynomials: parasite positive (red): concentration = m~1~\*(age in years) + c (n = 69); and parasite negative (black): concentration = m~1~\*ln(age in years) + c (n = 494); B) Log ferritin (x axis) with the fitted fractional polynomials: parasite positive (red): concentration = m~1~\*ln(ferritin) + c (n = 68); and parasite negative (black): concentration = m~1~\*ln(ln(ferritin + c~1~)) + m~2~\*(ln(ln(ferritin + c~1~)))^2^ + c~2~ (n = 489); C) Log sTfR (x axis) with the fitted fractional polynomials: parasite positive (red): concentration = m~1~\*ln(sTfR) + c (n = 69); and parasite negative (black): concentration = m~1~\*(ln sTfR)^3^ + m~2~\*(ln sTfR)^3^\*ln(ln sTfR) + c~1~ (n = 488); D) Log ferritin index (x axis) with the fitted fractional polynomials: parasite positive (red): concentration = m~1~\*ln(ferritin index) + c (n = 68); and parasite negative (black): concentration = m~1~\*(ln(ferritin index) + c~1~)^3^ + m~2~\*(ln(ferritin index))^3^\*ln(ln(ferritin index))^3^+ c~2~ (n = 475); E) Log CRP (x axis) with the fitted fractional polynomials: parasite positive (red): concentration = m~1~\*(ln(CRP) + c~1~)^2^ + c~2~ (n = 68); and parasite negative (black): concentration = m~1~\*ln(CRP) + c (n = 489); F) *P*. *falciparum* parasite density, parasites/μl (x axis) with the fitted fractional polynomial: Concentration = m~1~\*ln(parasite density) + c (n = 69). Dotted lines indicate 95% confidence intervals. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#f0010}

![Multiple fractional polynomials of the age profile of iron status and inflammation by malaria parasitaemia. Scatterplots of age in years (x axis) against A) log ferritin with the fitted fractional polynomials: for parasite positive (red): concentration = m~1~\*(age in years) + c (n = 69); and parasite negative (black): concentration = m~1~\*ln(age in years) + m~2~\*(ln(age in years))^2^ + c (n = 496); B) log soluble transferrin receptor with the fitted fractional polynomials: for parasite positive (red): concentration = m~1~\*(age in years) + c (n = 70); and parasite negative (black): concentration = m~1~\*(age in years)^− 0.5^ + m~2~\*(age in years)^− 0.5^ \*ln(age in years) + c (n = 498); C) log ferritin index with the fitted fractional polynomials for parasite positive (red): concentration = m~1~\*(age in years) + c (n = 69); and parasite negative (black): concentration = m~1~\*(age in years)^− 0.5^ + m~2~\*ln(age in years) + c (n = 481); and D) log CRP with the fitted fractional polynomials: for parasite positive (red): concentration = m~1~\*(age in years) + c (n = 69); and parasite negative (black): concentration = m~1~\*(age in years) + c (n = 496). Dotted lines indicate 95% confidence intervals. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![Malaria parasitaemia and inflammation influence hepcidin concentrations. Geometric mean hepcidin concentrations (and 95% confidence intervals) by malaria parasitaemia and inflammation for: A) all children and B) according to age group. P values are derived from GEE-based regression models, and analyses that included all ages were adjusted for age.](gr4){#f0020}

![Hepcidin concentrations following clinical malaria and non-malarial febrile illness. Scatterplots of log hepcidin concentration (y axis) against time since A) last clinical malarial episode (x axis) with fitted fractional polynomial, concentrations = m~1~\*(time since last clinical malarial episode) + c and B) last febrile non-malarial episode with fitted fractional polynomial, concentrations = m~1~\*(time since last febrile non-malarial episode) + c. Time was restricted to a 3 month period prior to hepcidin measurement.](gr5){#f0025}

![Kaplan--Meier curves of A) time to first clinical malarial episode according to tertile of hepcidin concentration (p = 0.43 for 1st tertile vs. 2nd tertile and p = 0.07 for 1st tertile vs. 3rd tertile); and B) time to first non-malarial fever episode according to tertile of hepcidin concentration (p = 0.50 for 1st tertile vs. 2nd tertile and p = 0.18 for 1st tertile vs. 3rd tertile). The range of hepcidin concentration for each hepcidin tertile was: 0·04--1·60 ng/ml for the 1st tertile; 1·61--7·49 ng/ml for the 2nd tertile; and 7·50--122·47 ng/ml for the 3rd tertile. P values are derived from Cox regression models.](gr6){#f0030}

###### 

Characteristics of study population (n = 324).

  Characteristics                                             
  ----------------------------------------------------------- ------------------
  Median age, mths[a](#tf0005){ref-type="table-fn"} (range)   47·0 (4·9, 97·1)
  Male sex, n (%)                                             177 (54·6)
  Haemoglobin AS, n (%)[b](#tf0010){ref-type="table-fn"}      45 (14·0)
  α^+^thalassemia, n (%)[c](#tf0015){ref-type="table-fn"}     
   αα/αα                                                      95 (30·3)
   αα/− α                                                     162 (51·8)
   − α/− α                                                    56 (17·9)
  Ethnic group, n (%)[d](#tf0020){ref-type="table-fn"}        
   Giriama                                                    279 (86·1)
   Chonyi                                                     28 (8·6)
   Kauma                                                      17 (5·3)

Defined as age at the mid-point of individual longitudinal follow up;

2 missing haemoglobin S type;

11 missing α^+^thalassaemia genotypes;

Subgroups of the Mijikenda ethnic group.

###### 

Effects of age on hepcidin, inflammation and iron status by malaria parasitaemia.

                                   Age, years                                                                          
  -------------------------------- -------------------- -------------------- --------------------- ------------------- -------------------
  Number, (%)                                           63 (10·6)            161 (27·1)            142 (24·0)          227 (38·3)
  Malaria parasitaemia, n (%)                           1 /62 (1·6)          10/155 (6·5)          21/141 (14·9)       38/224 (17·0)
  Parasite density, parasites/μL                        120                  1660 (327, 8406)      984 (380, 2545)     783 (407, 1505)
  Hepcidin, ng/ml                  All                  8·39 (5·85, 12·05)   2·49 (1·82, 3·41)     3·30 (2·39, 4·55)   1·47 (1·11, 1·95)
  Parasite + ve                    7·05                 4·92 (1·15, 21·15)   13·47 (7·35, 24·70)   3·14 (1·66, 5·95)   
  Parasite -ve                     8·42 (5·83, 12·17)   2·31 (1·66, 3·21)    2·56 (1·81, 3·64)     1·25 (0·91, 1·70)   
  CRP, mg/L                        All                  2·08 (1·44, 3·02)    1·29 (1·07, 1·57)     1·55 (1·22, 1·96)   0·89 (0·79, 1·02)
  Parasite + ve                    29                   2·48 (0·75, 8·14)    3·28 (1·45, 7·44)     1·74 (1·08, 2·78)   
  Parasite -ve                     1·99 (1·38, 2·87)    1·20 (1·0, 1·46)     1·32 (1·05, 1·67)     0·79 (0·70, 0·89)   
  Ferritin, μg/L                   All                  27·7 (19·5, 39·4)    11·0 (9·4, 13·0)      18·1 (15·3, 21·4)   14·8 (13·0, 16·9)
  Parasite + ve                    106                  30·4 (12·8, 72·3)    42·6 (29·3, 62·0)     21·5 (15·0, 30·8)   
  Parasite -ve                     27·0 (19·0, 38·6)    10·2 (8·7, 12·0)     15·4 (12·9, 18·3)     13·9 (12·1, 15·9)   
  sTfR, mg/L                       All                  3·44 (3·09, 3.83)    3·92 (3·72, 4·13)     3·38 (3·19, 3·58)   3·74 (3·53, 3·96)
  Parasite + ve                    5·09                 4·49 (3·61, 5·58)    3·02 (2·74, 3·32)     3·71 (3·19, 4·32)   
  Parasite -ve                     3·42 (3·07, 3·81)    3·88 (3·67, 4·11)    3·46 (3·24, 3·69)     3·74 (3·51, 3·98)   
  Ferritin index                   All                  2·54 (2·08, 3·09)    3·85 (3·48, 4·25)     2·82 (2·55, 3·11)   3·29 (3·00, 3·61)
  Parasite + ve                    2·51                 3·19 (2·05, 4·97)    1·89 (1·63, 2·19)     3·04 (2·33, 3·97)   
  Parasite -ve                     2·54 (2·08, 3·10)    3·90 (3·51, 4·34)    3·05 (2·73, 3·40)     3·35 (3·04, 3·69)   

Abbreviations: CRP, C-reactive protein; sTfR, soluble transferrin receptors. Parasite + ve indicates the presence of malaria parasites on routine blood smear. Unless otherwise indicated numbers are geometric means with 95% confidence intervals in brackets.

###### 

Cox regression models for risk of clinical malaria and non-malarial fever by hepcidin concentrations.

  -----------------------------------------------------------------------------------------------------------
  Clinical malaria[a](#tf0025){ref-type="table-fn"}     HR (95% CI)         p      Adjusted\           p
                                                                                   HR (95% CI)         
  ----------------------------------------------------- ------------------- ------ ------------------- ------
  Log Hepcidin (ng/ml)                                  0·85 (0·71, 1·01)   0·07   1·08 (0·90, 1·30)   0·41

  Hepcidin tertiles                                                                                    

   Hepcidin tertile 1                                   Reference           --     Reference           --

   Hepcidin tertile 2                                   0·85 (0·58, 1·26)   0·43   1·07 (0·72, 1·58)   0·75

   Hepcidin tertile 3                                   0·68 (0·45, 1·04)   0·07   1·00 (0·63, 1·58)   1·00

                                                                                                       

  Non-malarial fever[b](#tf0030){ref-type="table-fn"}   HR (95% CI)         p      Adjusted\           p
                                                                                   HR (95% CI)         

                                                                                                       

  Log hepcidin (ng/ml)                                  1·13 (0·91, 1·40)   0·25   1·02 (0·81, 1·27)   0·88

  Hepcidin tertiles                                                                                    

   Hepcidin tertile 1                                   Reference           --     Reference           --

   Hepcidin tertile 2                                   1·16 (0·75, 1·79)   0·50   1·05 (0·67, 1·63)   0·84

   Hepcidin tertile 3                                   1·34 (0·87, 2·05)   0·18   1·12 (0·72, 1·74)   0·61
  -----------------------------------------------------------------------------------------------------------

Abbreviations: HR, hazard ratio; CI, confidence interval. HRs and 95% CIs are shown for each log fold increase in hepcidin level and by hepcidin tertiles (tertile 1 = 0·04--1·60 ng/ml; tertile 2 = 1·61--7·49 ng/ml; tertile 3 = 7·50--122·47 ng/ml).

Defined as a fever (axillary temperature ≥ 37·5 °C) in conjunction with a positive blood film at any density for children age \< 1 year or at a density of \> 2500 parasites/μl for children aged ≥ 1 year ([@bb0010]). For clinical malaria HRs were adjusted for age in years, ethnicity, sickle cell trait, and period of monitoring.

Defined as a fever in conjunction with a negative blood film. For non-malarial fever HRs were adjusted for age in years and period of monitoring.
